chemXplore tracks 22 projects in Austria, of which 9 are active.
Of the active ones, 4 new construction, 4 expansion and 1 revamp / retrofit.
3 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Net GHGs down 1.6% in 2025; ETS revenues hit €43.2bn with €23.9bn to Member States; clean tech capacity and BEV uptake accelerated; faster action needed to meet 2030 targets.
Joint revamp targets ~10% lower specific energy at SKW unit 2 and major natural gas savings at LAT unit 2 via KBR KRES reformer; contracts signed end-September 2026.
Advances EU2 and EU3 ethane-cracker engineering with Linde; Borouge 4 adds 1.4 Mt polyethylene; Kallo PDH2 reaches mechanical completion; Burghausen and Schwechat projects progress.
Revenue rose 5% to $2.0B and adjusted EBITDA increased 12% to $268M; backlog reached $23.1B. Spin-off of Mission Technology Solutions (Trinzic) targeted for Jan 4, 2027 with Investor Days in November.
Messer deal secures a 10‑year supply pact and a 30% stake in four sites; 2026 revenue guided at €12–13m; German sales accelerating strongly; €45m cash and 36 MW installed capacity.
Revamps of 550 and 1,900 MTPD ammonia units will modernize reformers, add a new synthesis converter, cut natural gas use and lower CO₂ emissions.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.
active / all projects